Advertisement
|
|
news roundup
North Estonia Medical Centre (NEMC) has joined the network of hospitals on Clinerion's Patient Network Explorer platform. By joining this network, NEMC's clinical trials facilities will be exposed to a wide range of global clinical trials run by Clinerion's clients, international pharmaceutical companies, and CROs.
| Advertisement
Introducing Cross-Trial LMS: A Simple, Efficient, and Intuitive Way to Send Bulk Training
On Demand
 Read More |
LabCorp, a global life sciences company, and GENFIT, a late-stage biopharmaceutical company, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp's drug development business. The agreement hopes to expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.
The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization announced that it has launched a virtual fitness challenge to raise awareness and recognize clinical trial volunteers. This event encourages patients, professionals, and the public to show their support.
|
|
|
|
PAREXEL International Corporation, a provider of global biopharmaceutical services, introduced a new, dedicated division to help emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers » |
|
|
|
Articles
First column in our "Eye on Patient Advocacy" series looks at the effectiveness of digital marketing as an outreach tool.
In this Q&A, Helen Matthews, Jessica Morris, and Bruce Hellman offer their perspectives on the priorities, opportunities, and challenges of patient centricity in real-world evidence collection.
|
|
Blog Posts
DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.
RBM is an emerging area which gives endless opportunities to explore, transform, and evolve.
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription |
|
|
|
|
|
